|
⚲
|
| Keyboard |
| EcoR1 Capital LLC
✚
|
|
|---|---|
| CRD # | 167121 |
| SEC # | 801-100470 |
| CIK # | 0001587114 |
| AUM | 3,424.7 M (2026-03-30) |
| Employees | 22 (41% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 415-754-3517 |
| Address | 357 Tehama Street San Francisco, CA 94103 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Tue, 28 Jul 2026 | EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK — MarketBeat |
| Tue, 28 Jul 2026 | EcoR1 Capital LLC Cuts Stock Holdings in Xencor, Inc. $XNCR — MarketBeat |
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5. Fees and Compensation With respect to the Capital Funds, EcoR1 charges an annual management fee of 2.0% of each investor’s capital account balance, which amount is payable in quarterly installments at the beginning of each calendar quarter based on each investor’s capital account balance on that date. EcoR1 also typically receives a performance-based allocation with respect to each investor equal to 20% of net profits (including both realized and unrealized gains and losses) otherwise allocable to such investor. Performance allocations are assessed in arrears on an annual basis (and on withdrawals with respect to the amount withdrawn), and are only applied to the portion of profits that exceed the cumulative losses previously allocated to or incurred by clients. EcoR1 complies with Rule 205-3 under the Investment Advisers Act of 1940, to the extent required by applicable law. Performance allocations and fees may create an incentive for EcoR1 to make more risky and speculative investments than it would otherwise make. Investors in the Venture Funds and the SPVs are all “qualified purchasers” as defined in Section 2(a)(51) of the Investment Company Act of 1940. As a result, detailed information regarding the fees and compensation payable to EcoR1 and its affiliates by those funds is not required to be provided herein. EcoR1 and its affiliates are entitled to management fees and performance-based distributions from the Venture Funds that are calculated differently from the Capital Funds. EcoR1 does not receive a management fee from the existing SPV and the performance-based distributions are calculated differently from the Capital Funds. EcoR1 may waive or reduce all or any portion of the management or performance-based allocations and distributions with respect to any investor or client. EcoR1 deducts management fees and performance-based allocations and distributions directly from client accounts. To the extent that a client invests in mutual funds or ETFs, such client also bears indirectly the investment advisory fees to the managers of those funds. EcoR1 and its affiliates (including Mr. Nodelman) sit on company boards of directors or act as consultants to companies, in which companies EcoR1’s clients may have invested or may invest in the future. In such cases, EcoR1 or its affiliates may receive consideration for such services (including cash and securities). EcoR1 will waive a portion of the management fees to which it otherwise would be entitled in an amount equal to the value of such consideration. EcoR1 may choose to value the securities (such as options or warrants) and apply the management fee waiver as of the grant date, the exercise date or the date on which those securities are sold or become freely tradable. EcoR1 believes that its fees are competitive with fees charged by other investment advisers for comparable services. Comparable services may be available, however, from other sources for lower fees. Relationships with EcoR1’s investment fund clients are terminable on the termination of the applicable investment management agreement and, with respect to EcoR1’s investment partnership clients, on expiration of the partnership’s term, dissolution of the partnership or on EcoR1’s withdrawal as general partner. An investor in a Capital Fund may withdraw/redeem from that fund over eight consecutive withdrawal/redemption dates, on specified prior written notice, on the last day of any June or December beginning on or after the day preceding the first anniversary of such investor’s admission to the fund. Investors in the Venture Funds and the SPVs generally cannot withdraw from those funds but receive distributions when provided in the governing documents for those funds. In all cases, expenses, the pro rata portion of the management fee and the performance allocation or fee through the date of termination are charged to the account. All prepaid but unearned advisory fees are refunded on termination of a client’s account. An investor who withdraws from a fund on a date other than the last day of a quarter or other appropriate period, however, does not receive a refund of the management fee previously paid. Each fund or other client is responsible for its own costs and expenses as detailed in the governing documents for such fund. Such costs and expenses include, but are not limited to, trading costs and expenses (such as brokerage commissions, expenses related to short sales, and clearing and settlement charges), ongoing legal, accounting and bookkeeping fees and expenses, and the fees and expenses charged by any fund administrator for its accounting, bookkeeping and other services. The Capital Funds and the Venture Funds will likely bear more than their pro rata share of investment expenses (compared to the SPVs). For example, when EcoR1 identifies an investment opportunity, it will incur research and other out-of-pocket expenses, and will allocate those expenses between the Capital Funds and the Venture Funds on such basis as it determines fair and equitable. If an SPV is subsequently established and participates in that investment opportunity, that SPV may benefit from some or all of those earlier expenses without having to reimburse the Capital Funds or the Venture Funds. If an investment opportunity for an SPV is identified but not made, the Capital Funds and/or the Venture Funds would likely bear more than their pro rata share of any “broken deal” expenses. EcoR1 bears its own operating, general, administrative and overhead costs and expenses, other than the expenses described above. All or part of these costs and expenses may be paid, however, by securities brokerage firms and futures commission merchants that execute clients’ securities trades, as discussed in Item 12 below. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7. Types of Clients EcoR1 provides investment advice to investment funds and may provide investment advice to other accounts. Investors in the funds are required to invest a minimum of $25 million, but EcoR1 may waive this minimum. EcoR1 generally requires a minimum of $500 million to open an individually managed account, but may waive this minimum. EcoR1’s separate account clients may include high-net-worth individuals, institutions, trusts, endowments and pension plans. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Zymeworks Inc | 0.6 | ||
| Anaptysbio Inc | 0.4 | ||
| Jazz Pharmaceuticals Inc | 0.3 | ||
| Crinetics Pharmaceuticals Inc | 0.2 | ||
| Oric Pharmaceuticals Inc | 0.1 | ||
| CG Oncology Inc | 0.1 | ||
| CRISPR Therapeutics AG | 0.1 | ||
| Eton Pharmaceuticals Inc | 0.1 | ||
| Xencor Inc | 0.0 | ||
| Aquinox Pharmaceuticals Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | EcoR1 Venture Opportunity Fund LP | [2019-08-29] | 5.5 M | 65.4 M |
| Filed 2020-05-08 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $2,000,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | EcoR1 Special Opportunity Fund II LP | [2016-03-29] | 0.6 M | |
| Filed 2015-11-06 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | EcoR1 Special Opportunity Fund I LP | [2015-03-30] | 8.8 M | |
| Filed 2015-02-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | EcoR1 Capital Fund LP | [2014-03-25] | 117.8 M | 229.0 M |
| Filed 2026-01-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $25,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | EcoR1 Capital Fund Qualified LP | [2014-03-25] | 1,811.4 M | 3,130.2 M |
| Filed 2026-01-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $25,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 3.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 3.4 |
| By Discretionary | ||
| Discretionary | 5 | 3.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 3.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.7 | |
| United States Persons | 2.8 | |
| Total | 5 | 3.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Oleg Nodelman | Executive Officer | 14 | 3 | |
| Scott Perlen | Executive Officer | 8 | 2 | |
| Sarah Marriott | Executive Officer | 7 | 2 | |
| EcoR1 Capital LLC | Executive Officer | 5 | 2 | |
| Biotech Opportunity GP LLC | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001587114] | |
| 3 | [0001587114] | |
| 4 | [0001587114] | |
| SC 13D | [0001587114] | |
| SC 13G | [0001587114] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 254900G27UH5KKYMY240 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 2,077,779 | $18.00 | 37,400,022 |
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 128,506 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 202,862 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 2,270,879 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 144,443 | $18.00 | 2,599,974 |
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 9,913,810 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 997,299 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 488,891 | ||
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 2,397,500 | ||
|
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
|
2026-01-12 | Conversion | 965,190 | ||
|
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
|
2026-01-12 | Conversion | 86,222 | ||
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 102,500 | ||
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-30 | Sell | 27,433,338 | $0.10 | 2,743,334 |
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-29 | Sell | 2,687,460 | $0.10 | 268,746 |
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-28 | Sell | 33,931,740 | $0.11 | 3,732,491 |
|
Zymeworks Inc ZYME
Pre-Funded Warrants (right to acquire) · derivative
|
2025-06-26 | Option exercise | 5,086,521 | $0.00 | |
|
Zymeworks Inc ZYME
Common Stock
|
2025-06-26 | Option exercise | 5,086,480 | $0.00 | |
|
Zymeworks Inc ZYME
Common Stock
|
2025-06-26 | Tax withheld | 41 | $12.71 | 521 |
|
Zymeworks Inc ZYME
Common Stock
|
2025-05-19 | Buy | 5,919 | $11.78 | 69,726 |
|
Zymeworks Inc ZYME
Common Stock
|
2025-05-15 | Buy | 49,502 | $11.43 | 565,808 |
| showing 20 of 159 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Marble Bar Asset Management LLP
✚
|
3,568.3 M | |
|
JAHD Management Company LLC
✚
|
MA | 3,557.9 M |
|
Burkehill Global Management LP
✚
|
NY | 3,536.9 M |
|
Dragonfly Digital Management LLC
✚
|
CA | 3,437.5 M |
|
Carronade Capital Management LP
✚
|
CT | 3,431.8 M |
|
Caption Management LLC
✚
|
OK | 3,407.7 M |
|
Lakewood Capital Management LP
✚
|
NY | 3,398.7 M |
|
Invenomic Capital Management LP
✚
|
MA | 3,392.8 M |
|
Atalan Capital Partners LP
✚
|
NY | 3,290.1 M |
|
Verger Capital Management LLC
✚
|
NC | 3,283.7 M |